| Literature DB >> 31909379 |
Rabia Aydogan Baykara1, Ayca Tuzcu2, Ahmet Omma3, Gunseli Karaca Acet1, Erdal Dogan4, Almila Aydin1, Medine Cumhur Cure1, Erkan Cure1, Adem Kucuk1, Ozcan Erel1.
Abstract
OBJECTIVE: Increased reactive oxygen species may play an important role in Ankylosing spondylitis (AS) etiopathogenesis. The thiol group is a very potent antioxidant. In this study, we aimed to investigate the presence of oxidative stress in patients with AS by evaluating thiol/disulfide homeostasis.Entities:
Keywords: Ankylosing spondylitis; disulfide; oxidative stress; thiol; thiol/disulfide homeostasis
Year: 2018 PMID: 31909379 PMCID: PMC6936950 DOI: 10.14744/nci.2018.37132
Source DB: PubMed Journal: North Clin Istanb ISSN: 2536-4553
Sociodemographic characteristics of patients with AS
| AS patients (n=66) (mean±SD) | Control (n=66) (mean±SD) | p | |
|---|---|---|---|
| Age (years) | 37.3±9.9 | 38.3±11.4 | 0.617 |
| BMI (kg/m2) | 25.9±4.0 | 26.4±5.5 | 0.579 |
| Gender (Male/Female) (n) | 27/39 | 21/45 | 0.183 |
| Duration of disease (years) | |||
| (median [range]) | 3 (1–20) | ||
| Family history (n) | 10 | ||
| BASFI (n) | 3.5±2.6 | ||
| BASDAI (n) | 4.0±2.1 | ||
| Infliximab (n) | 1 | ||
| Etanercept (n) | 9 | ||
| Adalimumab (n) | 13 | ||
| Golimumab (n) | 7 | ||
| Only NSAID (n) | 18 | ||
| Salazopyrin (n) | 17 | ||
| Methotrexate (n) | 1 |
AS: Ankylosing spondylitis; BMI: Body mass index; BASFI: Bath Ankylosing Spondylitis Functional Index; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; NSAID: non-steroidal anti-inflammatory drug.
FIGURE 1Disulfide levels in Ankylosing spondylitis.
FIGURE 2Disulfide/Native thiol and disulfide/total thiol levels in Ankylosing spondylitis.
Thiol and other laboratory results of the AS and the control group
| AS patients (n=66) | Control (n=66) | p | |
|---|---|---|---|
| Native Thiol (µmol/l) | 325.4 (143.4–449.9) | 357.5 (245.9–482.6) | 0.001 |
| Total Thiol (µmol/l) | 367.0 (221.1–487.8) | 382.0 (274.1–517.2) | 0.065 |
| Native thiol/total thiol x100 | 87.9±4.8 | 93.8±2.4 | 0.001 |
| Disulfide (µmol/l) | 21.8±7.2 | 11.5±4.4 | 0.001 |
| Disulfide/native thiol x100 | 6.8±2.8 | 3.3±1.4 | 0.001 |
| Disulfide/total thiol x100 | 6.0±2.4 | 3.0±1.2 | 0.001 |
| ESR (mm/h) | 21.1±16.1 | 14.1±8.6 | 0.002 |
| CRP (mg/dl) | 0.5 (0.1–5.0) | 0.3 (0.1–1.9) | 0.002 |
| BUN (mg/dl) | 26.2±6.6 | 26.6±7.3 | 0.720 |
| Creatinine (mg/dl) | 0.7±0.1 | 0.6±0.1 | 0.002 |
| AST (IU/l) | 19.6±10.5 | 19.6±7.9 | 0.993 |
| ALT (IU/l) | 22.3±16.5 | 19.8±9.5 | 0.301 |
Mean±SD:
Median (range); AS: Ankylosing spondylitis; ESR: Erythrocyte sedimentation rate; CRP: C-reactive protein; BUN: Blood urea nitrogen; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase.
Results of correlation analysis for thiol levels in AS patients
| BASFI | BASDAI | Duration of disease | CRP | ESR | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| r | p | r | p | r | p | r | p | r | p | |
| Native thiol | -0.112 | 0.203 | -0.220 | 0.011 | -0.317 | 0.001 | -0.200 | 0.022 | -0.012 | 0.896 |
| Total thiol | -0.008 | 0.927 | -0.079 | 0.369 | -0.178 | 0.042 | -0.125 | 0.155 | -0.047 | 0.594 |
| Native thiol/total thiol | -0.300 | 0.001 | -0.450 | 0.001 | -0.599 | 0.001 | -0.273 | 0.002 | -0.118 | 0.178 |
| Disulfide | 0.353 | 0.001 | 0.496 | 0.001 | 0.573 | 0.001 | 0.234 | 0.007 | 0.191 | 0.029 |
| Disulfide/native thiol | 0.261 | 0.002 | 0.401 | 0.001 | 0.594 | 0.001 | 0.276 | 0.001 | 0.091 | 0.301 |
| Disulfide/total thiol | 0.299 | 0.001 | 0.449 | 0.001 | 0.596 | 0.001 | 0.277 | 0.001 | 0.119 | 0.173 |
| CRP | 0.219 | 0.002 | 0.263 | 0.002 | 0.332 | 0.001 | 1,00 | 0,001 | 0.520 | 0.001 |
| ESR | 0.318 | 0.001 | 0.413 | 0.001 | 0.217 | 0.012 | 0.520 | 0.001 | 1,00 | 0,001 |
| Duration of disease | 0.731 | 0.001 | 0.813 | 0.001 | 1,00 | 0,001 | 0.332 | 0.001 | 0.217 | 0.012 |
AS: Ankylosing spondylitis; BASFI: Bath Ankylosing Spondylitis Functional Index; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate.